See safety info and boxed warning. In a cohort of 27 participants, up to 77% reported enhancements in daily activities such as speech and eating after three months of treatment. The fda has approved austedo xr in four new tablet strengths for adults diagnosed with tardive dyskinesia and chorea associated with huntington’s disease, according to the manufacturer The most common adverse reactions for austedo (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia It is not known if austedo xr and austedo are safe and effective in children.
OPEN
